10% Owner Vivo Opportunity Buys $391K of InMed Pharmaceuticals Stock
INM has more than doubled off its 52-week low of $0.575.
Summary
Vivo Opportunity Cayman Fund, a 10% owner, significantly increased its stake in InMed Pharmaceuticals by purchasing $391,555 worth of common shares on the open market. This accumulation follows the company's recent merger announcement and comes amidst prior going concern warnings.
Key Events · Ownership and Investor Activity · INM
-
Significant Insider Accumulation
Vivo Opportunity Cayman Fund, a 10% owner, purchased $391,555 worth of common shares on the open market.
-
Post-Merger Confidence
The purchases occurred between May 20 and June 8, after InMed Pharmaceuticals announced an all-stock merger with Mentari Therapeutics on May 19.
-
Substantial Stake Increase
The transactions represent approximately 7.8% of the company's market capitalization.
-
Context of Financial Distress
These purchases follow a May 6 10-Q filing that disclosed substantial going concern doubt and a short cash runway.
Analysis · INM · Life Sciences
A 10% owner, Vivo Opportunity Cayman Fund, has made substantial open market purchases totaling $391,555, representing nearly 8% of InMed Pharmaceuticals' market capitalization. These purchases occurred between May 20 and June 8, following the company's announcement of an all-stock merger with Mentari Therapeutics on May 19. This accumulation by a significant institutional investor suggests confidence in the company's strategic direction and the potential of the merger, especially given the prior disclosure of going concern doubt in the May 6 10-Q.
At the time of this filing, INM was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.58 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.